The emergence of antibody therapies for Ebola

Human Antibodies

Volumn 23, Issue 3-4, 2015, Pages 49-56

  Hiatt, Andrew ^a   Pauly, Michael ^a   Whaley, Kevin ^a   Qiu, Xiangguo ^b   Kobinger, Gary ^b   Zeitlin, Larry ^a  

^a Mapp Biopharmaceutical Inc   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Ebola antibody discovery; Ebola virus; effector functions; passive immunotherapy

Indexed keywords

IMMUNOGLOBULIN G; ZMAPP; EPITOPE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

AFRICA; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS NEUTRALIZATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; EBOLAVIRUS; GENETICS; GLYCOSYLATION; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE; PASSIVE IMMUNIZATION; PATHOGENICITY; PROCEDURES; PROTEIN ENGINEERING; RHESUS MONKEY; SURVIVAL ANALYSIS; TRANSGENIC PLANT; VIROLOGY;

AFRICA, WESTERN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; EBOLAVIRUS; EPITOPES; GLYCOSYLATION; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA MULATTA; MICE; PLANTS, GENETICALLY MODIFIED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 84954162282     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-150284     Document Type: Review

References (42)

1. M.T. Osterhol et al., Transmission of Ebola viruses: What we know and what we do not know, mBio 6(2) (2015), e00137.
2. H. Ebihara et al., Molecular determinants of Ebola virus virulence in mice, PLoS Pathogens 2(7) (2006), e73.
3. A. Hiatt and M. Pauly, Monoclonal antibodies from plants: A new speed record, Proceedings of the National Academy of Sciences of the United States of America 103(40) (2006), 14645-14646.
4. X. Qiu et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature 514(7520) (2014), 47-53.
5. A.L. Schmaljohn, Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts, Current HIV research 11(5) (2013), 345-353.
6. M. Goeijenbier, J.J. van Kampen, C.B. Reusken, M.P. Koopmans and E.C. van Gorp, Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis, The Netherlands Journal of Medicine 72(9) (2014), 442-448.
7. T. Maruyama et al., Ebola virus can be effectively neutralized by antibody produced in natural human infection, Journal of Virology 73(7) (1999), 6024-6030.
8. T. Maruyama et al., Recombinant human monoclonal antibodies to Ebola virus, The Journal of Infectious Diseases 179(Suppl 1) (1999), S235-S239.
9. P.W. Parren, T.W. Geisbert, T. Maruyama, P.B. Jahrling and D.R. Burton, Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody, Journal of Virology 76(12) (2002), 6408-6412.
10. P.B. Jahrling, J.B. Geisbert, J.R. Swearengen, T. Larsen and T.W. Geisbert, Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates, The Journal of Infectious Diseases 196(Suppl 2) (2007), S400-S403.
11. D.J. Shedlock et al., Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms, Virology 401(2) (2010), 228-235.
12. J.M. Dias et al., A shared structural solution for neutralizing ebolaviruses, Nature Structural & Molecular Biology 18(12) (2011), 1424-1427.
13. A. Sanchez and P.E. Rollin, Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda, Virus Research 113(1) (2005), 16-25.
14. S.I. Okware et al., An outbreak of Ebola in Uganda, Tropical Medicine & International Health: TM & IH 7(12) (2002), 1068-1075.
15. J.A. Wilson et al., Epitopes involved in antibody-mediated protection from Ebola virus, Science (New York, N.Y.) 287(5458) (2000), 1664-1666.
16. A. Sanchez, S.G. Trappier, B.W. Mahy, C.J. Peters and S.T. Nichol, The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing, Proceedings of the National Academy of Sciences of the United States of America 93(8) (1996), 3602-3607.
17. V.E. Volchkov, V.A. Volchkova, W. Slenczka, H.D. Klenk and H. Feldmann, Release of viral glycoproteins during Ebola virus infection, Virology 245(1) (1998), 110-119.
18. Z. Euler and G. Alter, Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication, AIDS Research and Human Retroviruses 31(1) (2015), 13-24.
19. A. Takada, H. Feldmann, T.G. Ksiazek and Y. Kawaoka, Antibody-dependent enhancement of Ebola virus infection, Journal of Virology 77(13) (2003), 7539-7544.
20. A. Takada, S. Watanabe, K. Okazaki, H. Kida and Y. Kawaoka, Infectivity-enhancing antibodies to Ebola virus glycoprotein, Journal of Virology 75(5) (2001), 2324-2330.
21. G.M. Ignatyev, Immune response to filovirus infections, Cur rent Topics in Microbiology and Immunology 235 (1999), 205-217.
22. A. Takada, H. Ebihara, H. Feldmann, T.W. Geisbert and Y. Kawaoka, Epitopes required for antibody-dependent enhancement of Ebola virus infection, The Journal of Infectious Diseases 196(Suppl 2) (2007), S347-S356.
23. T.W. Geisbert, L.E. Hensley, J.B. Geisbert and P.B. Jahrling, Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections, Virology 293(1) (2002), 15-19.
24. K. Mupapa et al., Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients, International Scientific and Technical Committee, The Journal of Infectious Diseases 179(Suppl 1) (1999), S18-S23.
25. J.M. Dye et al., Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease, Proceedings of the National Academy of Sciences of the United States of America 109(13) (2012), 5034-5039.
26. A. Takada, H. Ebihara, S. Jones, H. Feldmann and Y. Kawaoka, Protective efficacy of neutralizing antibodies against Ebola virus infection, Vaccine 25(6) (2007), 993-999.
27. A. Marzi et al., Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever, PloS One 7(4) (2012), e36192.
28. Z. Huang et al., High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system, Biotechnology and Bioengineering 106(1) (2010), 9-17.
29. Q. Chen, J. He, W. Phoolcharoen and H.S. Mason, Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants, Human Vaccines 7(3) (2011), 331-338.
30. A. Giritch et al., Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors, Proceedings of the National Academy of Sciences of the United States of America 103(40) (2006), 14701-14706.
31. R. Strasser, F. Altmann and H. Steinkellner, Controlled glycosylation of plant-produced recombinant proteins, Current Opinion in Biotechnology 30 (2014), 95-100.
32. A. Castilho et al., In planta protein sialylation through overexpression of the respective mammalian pathway, The Journal of Biological Chemistry 285(21) (2010), 15923-15930.
33. R. Strasser et al., Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure, Plant Biotechnology Journal 6(4) (2008), 392-402.
34. L. Zeitlin et al., Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant, Proceedings of the National Academy of Sciences of the United States of America 108(51) (2011), 20690-20694.
35. X. Qiu et al., Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies, Clinical Immunology (Orlando, Fla.) 141(2) (2011), 218-227.
36. X. Qiu et al., Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection, PLoS Neglected Tropical Diseases 6(3) (2012), e1575.
37. X. Qiu et al., Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies, Science Translational Medicine 4(138) (2012), 138-181.
38. X. Qiu et al., Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb, Scientific Reports 3 (2013), 3365.
39. G.G. Olinger, Jr. et al., Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques, Proceedings of the National Academy of Sciences of the United States of America 109(44) (2012), 18030-18035.
40. J. Pettitt et al., Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail, Science Translational Medicine 5(199) (2013), 199ra113.
41. G.P. Pogue et al., Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems, Plant Biotechnology Journal 8(5) (2010), 638-654.
42. V. Klimyuk, G. Pogue, S. Herz, J. Butler and H. Haydon, Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMPcompliant facilities for small-and large-scale manufacturing, Current Topics in Microbiology and Immunology 375 (2014), 127-154.